Table 3.
Patients’ clinical outcomes according to metformin subgroups.
| CON | N-MFOM | MFOM | P | |
|---|---|---|---|---|
| Acute kidney injury | 9 (0.7) | 3 (3.3) | 8 (1.7) | 0.021 |
| Inotrope use | 73 (5.6) | 9 (9.5) | 39 (8.3) | 0.060 |
| Conventional oxygen therapy | 302 (23.2) | 36 (37.9) | 136 (29.0) | <0.001 |
| High-flow nasal cannula | 69 (5.3) | 5 (5.3) | 40 (8.5) | 0.041 |
| Mechanical ventilation | 47 (3.6) | 7 (7.4) | 31 (6.6) | 0.012 |
| Extracorporeal membrane oxygenation | 6 (0.5) | 2 (2.1) | 5 (1.1) | 0.096 |
| Cardiac arrest | 3 (0.2) | 1 (1.1) | 3 (0.6) | 0.250 |
| Myocardial infarction | 3 (0.2) | 1 (1.1) | 2 (0.4) | 0.354 |
| Acute heart failure | 5 (0.4) | 0 | 0 | 0.337 |
Data are expressed as n (%); CON, patients not taking diabetic drugs; N-MFOM, patients taking diabetic medications other than metformin; MFOM, patients taking metformin.